Court tosses fired DEIA officer’s lawsuit over Trump DEI order
She got an ultimatum. Her non-DEIA colleagues allegedly got a better deal
Pharmaceutical manufacturer Eli Lilly recently rolled out a new platform intended to boost employer coverage of GLP-1 medications for obesity.Lilly will offer Zepbound, an injectable GLP-1 medication, at a price of $449 per month for all doses through the platform, called Lilly Connect. That’s the same price for higher doses